These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 20233183)

  • 1. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.
    Fang ZZ; Zhang YY; Ge GB; Huo H; Liang SC; Yang L
    Br J Clin Pharmacol; 2010 Feb; 69(2):193-9. PubMed ID: 20233183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cytochrome P450 (CYP) isoforms involved in the metabolism of corynoline, and assessment of its herb-drug interactions.
    Fang ZZ; Zhang YY; Ge GB; Liang SC; Sun DX; Zhu LL; Dong PP; Cao YF; Yang L
    Phytother Res; 2011 Feb; 25(2):256-63. PubMed ID: 20641061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside.
    Sun DX; Lu JC; Fang ZZ; Zhang YY; Cao YF; Mao YX; Zhu LL; Yin J; Yang L
    Phytother Res; 2010 Nov; 24(11):1670-5. PubMed ID: 21031626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro.
    Wang X; Cheung CM; Lee WY; Or PM; Yeung JH
    Phytomedicine; 2010 Sep; 17(11):868-75. PubMed ID: 20638257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: implication for clinical drug-drug interactions.
    Song JH; Sun DX; Chen B; Ji DH; Pu J; Xu J; Tian FD; Guo L
    J Biosci; 2011 Dec; 36(5):879-85. PubMed ID: 22116286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.
    Zhang N; Seguin RP; Kunze KL; Zhang YY; Jeong H
    Drug Metab Dispos; 2013 Dec; 41(12):2114-23. PubMed ID: 24046330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes.
    Berry LM; Zhao Z
    Drug Metab Lett; 2008 Jan; 2(1):51-9. PubMed ID: 19356071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes.
    Qi XY; Liang SC; Ge GB; Liu Y; Dong PP; Zhang JW; Wang AX; Hou J; Zhu LL; Yang L; Tu CX
    Food Chem Toxicol; 2013 Jun; 56():392-7. PubMed ID: 23500771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically significant CYP2C inhibition by noscapine but not by glucosamine.
    Rosenborg S; Stenberg M; Otto S; Ostervall J; Masquelier M; Yue QY; Bertilsson L; Eliasson E
    Clin Pharmacol Ther; 2010 Sep; 88(3):343-6. PubMed ID: 20668444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
    Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of deoxypodophyllotoxin from Anthriscus sylvestris on human CYP2C9 and CYP3A4.
    Lee SK; Kim Y; Jin C; Lee SH; Kang MJ; Jeong TC; Jeong SY; Kim DH; Yoo HH
    Planta Med; 2010 May; 76(7):701-4. PubMed ID: 19960413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
    Yeung JH; Or PM
    Phytomedicine; 2012 Mar; 19(5):457-63. PubMed ID: 22305191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
    Derks M; Fowler S; Kuhlmann O
    Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
    Mao J; Johnson TR; Shen Z; Yamazaki S
    Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
    He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
    Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
    Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.